Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Dianthus Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $40.7 million for Q3 2025.

• On a quarterly basis, Operating Expenses rose 26.85% year-over-year to $40.7 million in Q3 2025; TTM through Dec 2025 was $110.1 million, a 1.89% increase from a year earlier, with the FY2024 full-year figure at $108.1 million, up 111.96% from the prior year.
• Operating Expenses grew to $40.7 million in Q3 2025 per DNTH's latest filing, from $35.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $40.7 million in Q3 2025 and bottomed at $8.2 million in Q1 2023.
• The 5-year median for Operating Expenses is $18.7 million (2021), against an average of $21.4 million.
• Across the five-year window, Operating Expenses slumped 65.77% in 2023 and jumped 147.83% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $20.1 million in 2021, then slumped by 41.07% to $11.9 million in 2022, then advanced by 13.02% to $13.4 million in 2023, then soared by 147.83% to $33.2 million in 2024, then climbed by 22.39% to $40.7 million in 2025.
• Per Business Quant, the three latest DNTH Operating Expenses figures stand at $40.7 million (Q3 2025), $35.1 million (Q2 2025), and $34.3 million (Q1 2025).